MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.

MLA

Tesileanu, C.Mircea S., et al. “MGMT Promoter Methylation Determined by the MGMT-STP27 Algorithm Is Not Predictive for Outcome to Temozolomide in IDH-Mutant Anaplastic Astrocytomas.” Neuro-Oncology, vol. 24, no. 4, Apr. 2022, pp. 665–67. EBSCOhost, https://doi.org/10.1093/neuonc/noac014.

APA

Tesileanu, C. M. S., Gorlia, T., Golfinopoulos, V., French, P. J., & van den Bent, M. J. (2022). MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. Neuro-Oncology, 24(4), 665–667. https://doi.org/10.1093/neuonc/noac014

Chicago

Tesileanu, C Mircea S, Thierry Gorlia, Vassilis Golfinopoulos, Pim J French, and Martin J van den Bent. 2022. “MGMT Promoter Methylation Determined by the MGMT-STP27 Algorithm Is Not Predictive for Outcome to Temozolomide in IDH-Mutant Anaplastic Astrocytomas.” Neuro-Oncology 24 (4): 665–67. doi:10.1093/neuonc/noac014.